3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Leukemia, Myeloid, Acute
54
Multiple Myeloma
45
Lymphoma
44
Lymphoma, Non-Hodgkin
41
Leukemia
38
Precursor Cell Lymphoblastic Leukemia-Lymphoma
35
Hodgkin Disease
35
Myelodysplastic Syndromes
34
Lymphoma, Mantle-Cell
20
Lymphoma, Large B-Cell, Diffuse
19
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
19
Leukemia, Lymphocytic, Chronic, B-Cell
16
Burkitt Lymphoma
16
Breast Neoplasms
13
Neoplasms, Plasma Cell
11
Recurrence
10
Lymphoma, Follicular
10
Hematologic Neoplasms
9
Anemia, Refractory, with Excess of Blasts
9
Lymphoma, B-Cell, Marginal Zone
8
Neuroblastoma
7
Myeloproliferative Disorders
7
Lymphoma, Large-Cell, Immunoblastic
7
Central Nervous System Neoplasms
7
Blast Crisis
7
Neoplasms
6
Lymphoma, T-Cell
6
Leukemia, Myelomonocytic, Juvenile
6
Leukemia, Myelomonocytic, Chronic
6
Graft vs Host Disease
6
Interventions
Carboplatin
79
pembrolizumab
64
Paclitaxel
64
Cyclophosphamide
47
Capecitabine
34
Doxorubicin
31
Taxes
28
130-nm albumin-bound paclitaxel
28
Albumin-Bound Paclitaxel
27
Gemcitabine
20
atezolizumab
18
Epirubicin
18
Cisplatin
18
Bevacizumab
18
olaparib
17
sacituzumab govitecan
15
Docetaxel
15
eribulin
14
toripalimab
13
durvalumab
13
camrelizumab
13
Drug Therapy
12
apatinib
9
Trastuzumab
9
Radiotherapy
9
Specimen Handling
8
Magnetic Resonance Spectroscopy
8
Biopsy
8
tislelizumab
7
talazoparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Triple Negative Breast Neoplasms
×
Granulocyte Colony-Stimulating Factor
×
Clear all
NCT05520723
2025-12-04
PRIMED
MedSIR
Phase 2
Completed
50 enrolled